https://gawel.ch/ 2026-06-01 monthly 1.0 https://gawel.ch/images/Profilbild.webp Dr. Claus Gawel - Managing Director https://gawel.ch/fee-structure/ 2026-06-01 monthly 0.8 https://gawel.ch/fractional-counsel/ 2026-06-01 monthly 0.8 https://gawel.ch/biotech-pharma/ 2026-06-01 monthly 0.8 https://gawel.ch/medtech/ 2026-06-01 monthly 0.8 https://gawel.ch/ict-digital-health/ 2026-06-01 monthly 0.8 https://gawel.ch/services/ 2026-05-31 monthly 0.8 https://gawel.ch/services/eu-ai-act-compliance/ 2026-05-31 monthly 0.7 https://gawel.ch/services/swiss-data-protection-representative/ 2026-05-31 monthly 0.7 https://gawel.ch/services/ch-rep-swiss-authorized-representative/ 2026-05-31 monthly 0.7 https://gawel.ch/services/cyber-digital-resilience/ 2026-05-31 monthly 0.7 https://gawel.ch/services/market-access-reimbursement-switzerland/ 2026-05-31 monthly 0.7 https://gawel.ch/services/pharmacovigilance-drug-safety/ 2026-05-31 monthly 0.7 https://gawel.ch/services/product-liability-switzerland/ 2026-05-31 monthly 0.7 https://gawel.ch/services/health-research-data-law/ 2026-05-31 monthly 0.7 https://gawel.ch/services/life-sciences-regulatory-counsel/ 2026-05-31 monthly 0.7 https://gawel.ch/services/mdr-ivdr-compliance/ 2026-05-31 monthly 0.7 https://gawel.ch/services/clinical-trial-contracting/ 2026-05-31 monthly 0.7 https://gawel.ch/services/data-protection-advisor/ 2026-05-31 monthly 0.7 https://gawel.ch/services/ict-commercial-contracting/ 2026-05-31 monthly 0.7 https://gawel.ch/services/digital-health-compliance/ 2026-05-31 monthly 0.7 https://gawel.ch/services/pharma-medtech-transactions/ 2026-05-31 monthly 0.7 https://gawel.ch/services/international-arbitration/ 2026-05-31 monthly 0.7 https://gawel.ch/services/pharma-compliance-investigations/ 2026-05-31 monthly 0.7 https://gawel.ch/contact/ 2026-06-01 monthly 0.7 https://gawel.ch/legal-notice/ 2026-06-01 yearly 0.3 https://gawel.ch/privacy-policy/ 2026-06-01 yearly 0.3 https://gawel.ch/accessibility/ 2026-06-01 yearly 0.3 https://gawel.ch/regulatory-tracker/ 2026-05-28 monthly 0.8 https://gawel.ch/insights/ 2026-03-31 monthly 0.8 https://gawel.ch/insights/01-pharma-rnd-partnerships/ 2025-09-16 yearly 0.7 https://gawel.ch/insights/02-biotech-clinical-manufacturing/ 2025-09-18 yearly 0.7 https://gawel.ch/insights/03-gdpr-clinical-trials/ 2025-09-23 yearly 0.7 https://gawel.ch/insights/04-pharma-supply-chain-liability/ 2025-09-25 yearly 0.7 https://gawel.ch/insights/05-swiss-authorized-representative-mdr/ 2025-09-30 yearly 0.7 https://gawel.ch/insights/06-atmp-licensing-hospital-exemption/ 2025-10-02 yearly 0.7 https://gawel.ch/insights/07-samd-classification-pitfalls/ 2025-10-07 yearly 0.7 https://gawel.ch/insights/08-pharma-distribution-parallel-imports/ 2025-10-09 yearly 0.7 https://gawel.ch/insights/09-swiss-professional-secrecy-ediscovery/ 2025-10-14 yearly 0.7 https://gawel.ch/insights/10-regulatory-sandbox-digital-health/ 2025-10-16 yearly 0.7 https://gawel.ch/insights/11-samd-clinical-evidence/ 2025-10-21 yearly 0.7 https://gawel.ch/insights/12-samd-post-market-surveillance/ 2025-10-28 yearly 0.7 https://gawel.ch/insights/14-ai-medical-devices/ 2025-11-27 yearly 0.7 https://gawel.ch/insights/15-eu-mdr-compliance/ 2025-12-02 yearly 0.7 https://gawel.ch/insights/16-ai-drug-discovery-ip/ 2025-12-04 yearly 0.7 https://gawel.ch/insights/17-cloud-contracts-jurisdiction/ 2025-12-09 yearly 0.7 https://gawel.ch/insights/13-biotech-licensing-pitfalls/ 2025-11-25 yearly 0.7 https://gawel.ch/insights/19-nis2-medtech-cybersecurity/ 2025-12-30 yearly 0.7 https://gawel.ch/insights/20-cross-border-clinical-trial-agreements/ 2026-01-06 yearly 0.7 https://gawel.ch/insights/21-swiss-medtech-export/ 2026-01-08 yearly 0.7 https://gawel.ch/insights/22-biotech-ma-earnouts/ 2026-01-27 yearly 0.7 https://gawel.ch/insights/18-samd-cybersecurity/ 2025-12-23 yearly 0.7 https://gawel.ch/insights/23-swiss-pharma-pricing-rnd/ 2026-02-03 yearly 0.7 https://gawel.ch/insights/24-eu-ai-act-german-pharma-rnd/ 2026-02-05 yearly 0.7 https://gawel.ch/insights/25-austria-clinical-trial-pathway/ 2026-02-10 yearly 0.7 https://gawel.ch/insights/26-nordic-nis2-pharma-rnd/ 2026-02-12 yearly 0.7 https://gawel.ch/insights/27-swiss-clinical-trials-pregnant-participants/ 2026-02-17 yearly 0.7 https://gawel.ch/insights/30-comparative-clinical-trials-pregnant-participants/ 2026-03-05 yearly 0.7 https://gawel.ch/insights/28-eu-clinical-trials-pregnant-participants/ 2026-02-19 yearly 0.7 https://gawel.ch/insights/29-us-clinical-trials-pregnant-participants/ 2026-03-03 yearly 0.7 https://gawel.ch/insights/31-eu-pharma-package-global-filing-90-day-rule/ 2026-03-10 yearly 0.7 https://gawel.ch/insights/32-eu-pharma-package-orphan-product-based-exclusivity/ 2026-03-12 yearly 0.7 https://gawel.ch/insights/33-eu-pharma-package-access-conditionality-article-56a/ 2026-03-17 yearly 0.7 https://gawel.ch/insights/34-eu-pharma-package-bolar-expansion-tender-entry/ 2026-03-19 yearly 0.7 https://gawel.ch/insights/35-eu-pharma-package-tev-antimicrobial-pull-incentive/ 2026-03-24 yearly 0.7 https://gawel.ch/insights/36-eu-pharma-package-era-supply-chain-non-eu-manufacturing/ 2026-03-26 yearly 0.7 https://gawel.ch/insights/37-eu-pharma-package-regulatory-sandbox-novel-therapies/ 2026-03-31 yearly 0.7 https://gawel.ch/insights/38-swiss-employee-inventions-art-332-or/ 2026-04-02 yearly 0.7 https://gawel.ch/insights/39-liability-allocation-us-swiss-rnd-collaborations/ 2026-04-07 yearly 0.7 https://gawel.ch/insights/40-eu-data-act-us-cloud-iot-contracts/ 2026-04-09 yearly 0.7 https://gawel.ch/insights/41-ivdr-transition-swiss-ivdv-us-ivd-makers/ 2026-04-14 yearly 0.7 https://gawel.ch/insights/42-eu-cyber-resilience-act-us-vendors/ 2026-04-16 yearly 0.7 https://gawel.ch/insights/43-austria-nis2-pharma-rnd/ 2026-04-21 yearly 0.7 https://gawel.ch/insights/44-eu-pharma-package-us-sponsor-decisions/ 2026-04-23 yearly 0.7 https://gawel.ch/insights/45-eu-pharma-package-critical-medicines-joint-procurement/ 2026-04-28 yearly 0.7 https://gawel.ch/insights/46-pharma-promotion-fda-opdp-vs-swiss-eu/ 2026-04-30 yearly 0.7 https://gawel.ch/insights/47-eu-hta-joint-clinical-assessment-year-one/ 2026-05-05 yearly 0.7 https://gawel.ch/insights/48-eu-product-liability-directive-us-pharma-supply-chains/ 2026-05-07 yearly 0.7 https://gawel.ch/insights/49-hfg-dsg-clinical-trial-consent/ 2026-05-12 yearly 0.7 https://gawel.ch/insights/50-diga-outcome-based-pricing-digital-therapeutics/ 2026-05-14 yearly 0.7 https://gawel.ch/insights/51-eu-ai-act-mdr-medical-ai-cliff/ 2026-05-19 yearly 0.7 https://gawel.ch/insights/52-eu-ai-act-gpai-us-foundation-models/ 2026-05-21 yearly 0.7 https://gawel.ch/insights/53-bilaterals-iii-swiss-mra-us-medtech/ 2026-05-26 yearly 0.7 https://gawel.ch/insights/54-ehds-us-biotech-secondary-use/ 2026-05-28 yearly 0.7 https://gawel.ch/insights/55-technology-transfer-block-exemption-eu-uk-swiss/ 2026-06-02 yearly 0.7 https://gawel.ch/insights/56-eu-foreign-subsidies-regulation-us-biotech-ma/ 2026-06-04 yearly 0.7 https://gawel.ch/insights/57-eudamed-mandatory-registration-us-devices/ 2026-06-09 yearly 0.7 https://gawel.ch/insights/58-swiss-isg-cyber-incident-reporting-critical-infrastructure/ 2026-06-11 yearly 0.7 https://gawel.ch/insights/59-germany-mfg-confidential-pricing-rnd-location/ 2026-06-16 yearly 0.7 https://gawel.ch/insights/60-soho-regulation-cell-gene-therapy-us-biotech/ 2026-06-18 yearly 0.7 https://gawel.ch/insights/61-switzerland-ai-regulation-vs-eu-ai-act/ 2026-06-23 yearly 0.7 https://gawel.ch/insights/62-swiss-kartellgesetz-siec-weko-merger-control/ 2026-06-25 yearly 0.7 https://gawel.ch/insights/63-eu-digital-omnibus-us-tech-life-sciences/ 2026-06-30 yearly 0.7 https://gawel.ch/insights/64-transatlantic-data-transfers-dpf/ 2026-07-02 yearly 0.7 https://gawel.ch/insights/65-upc-year-three-opt-out-us-portfolios/ 2026-07-07 yearly 0.7 https://gawel.ch/insights/66-digital-omnibus-gdpr-cookie-reform-us-saas/ 2026-07-09 yearly 0.7